SAN

80.94

+0.38%↑

SHL.DE

42.28

+1%↑

PHIA

26.89

+0.9%↑

SRT3

238

-0.17%↓

ORNBV.FI

67.95

-0.22%↓

SAN

80.94

+0.38%↑

SHL.DE

42.28

+1%↑

PHIA

26.89

+0.9%↑

SRT3

238

-0.17%↓

ORNBV.FI

67.95

-0.22%↓

SAN

80.94

+0.38%↑

SHL.DE

42.28

+1%↑

PHIA

26.89

+0.9%↑

SRT3

238

-0.17%↓

ORNBV.FI

67.95

-0.22%↓

SAN

80.94

+0.38%↑

SHL.DE

42.28

+1%↑

PHIA

26.89

+0.9%↑

SRT3

238

-0.17%↓

ORNBV.FI

67.95

-0.22%↓

SAN

80.94

+0.38%↑

SHL.DE

42.28

+1%↑

PHIA

26.89

+0.9%↑

SRT3

238

-0.17%↓

ORNBV.FI

67.95

-0.22%↓

Search

Fagron

Uždarymo kaina

SektoriusSveikatos priežiūra

22.35 1.36

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

22

Max

22.35

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-99K

45M

Pardavimai

-98K

476M

P/E

Sektoriaus vid.

18.932

108.767

Dividendų pajamingumas

1.82

Pelno marža

9.55

Darbuotojai

3,989

EBITDA

11M

98M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+20.59% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

1.82%

2.21%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-7.3M

1.6B

Ankstesnė atidarymo kaina

20.99

Ankstesnė uždarymo kaina

22.35

Naujienos nuotaikos

By Acuity

50%

50%

167 / 351 reitingas Healthcare

Fagron Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-25 23:25; UTC

Karštos akcijos

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

2026-02-25 23:15; UTC

Uždarbis

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

2026-02-25 23:54; UTC

Rinkos pokalbiai

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

2026-02-25 23:47; UTC

Uždarbis

Ferrovial 4Q Net EUR197M >FER.MC

2026-02-25 23:45; UTC

Uždarbis

Ferrovial 4Q Rev EUR2.72B >FER.MC

2026-02-25 23:42; UTC

Uždarbis

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

2026-02-25 23:38; UTC

Rinkos pokalbiai

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

2026-02-25 23:25; UTC

Uždarbis

Trip.com: Company's Business Operations Remain Normal >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com FY EPS CNY47.67 >TCOM

2026-02-25 23:06; UTC

Uždarbis

Correction to Nvidia Fourth Quarter Results Article -- WSJ

2026-02-25 23:01; UTC

Uždarbis

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

2026-02-25 23:00; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

2026-02-25 23:00; UTC

Rinkos pokalbiai
Uždarbis

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

2026-02-25 22:56; UTC

Rinkos pokalbiai
Uždarbis

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

2026-02-25 22:43; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

2026-02-25 22:40; UTC

Rinkos pokalbiai
Uždarbis

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

2026-02-25 22:40; UTC

Uždarbis

Karoon Energy Says Search for New CFO Well Advanced

2026-02-25 22:39; UTC

Uždarbis

Karoon Energy Says CFO Ray Church to Leave Company

2026-02-25 22:39; UTC

Uždarbis

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

2026-02-25 22:38; UTC

Uždarbis

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Akcijų palyginimas

Kainos pokytis

Fagron Prognozė

Kainos tikslas

By TipRanks

20.59% į viršų

12 mėnesių prognozė

Vidutinis 19.5 EUR  20.59%

Aukščiausias 19.5 EUR

Žemiausias 19.5 EUR

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Fagron kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

167 / 351 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Fagron

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
help-icon Live chat